Drugs commonly used in the treatment of rheumatic diseases are non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, anti-rheumatic drugs to improve the condition, botanicals, biological agents, etc. (1) non-steroidal anti-inflammatory drugs (NSAIDs): the role of such drugs are antipyretic, anti-inflammatory and analgesic, and to reduce the inflammatory response and purpose. Commonly used are ibuprofen, meloxicam, piroxicam, naproxen, loxoprofen sodium, celecoxib, etoricoxib, etc. The main gastrointestinal adverse reactions, liver and kidney damage, avoid the simultaneous use of 2 and more drugs of this class. (2) Glucocorticoids: These drugs have strong anti-inflammatory, anti-allergic and immunosuppressive effects, and have a strong and rapid elimination of inflammation and various symptoms brought about by inflammatory reactions, such as fever, joint swelling and pain. Clinical applications include short-acting, intermediate-acting and long-acting preparations. They can be administered orally, intramuscularly or intra-articularly, or intravenously, depending on the type of disease and condition. The side effects of long-term glucocorticosteroids should be noted, including masking infection, osteoporosis, femoral head necrosis, diabetes, peptic ulcer, hypertension and mental abnormality, etc. Also, if the drug is discontinued too quickly, the disease may rebound. Except for patients with severe diseases, in principle, small doses and short courses of treatment are appropriate. (3) Anti-rheumatic drugs to improve the disease (DMARDs): also known as slow-acting anti-rheumatic drugs. DMARDs include chloroquine, hydroxychloroquine, salbutamol, methotrexate, azathioprine, cyclophosphamide, penicillamine, gold, cyclosporine A and leflunomide. A and leflunomide, etc. (4) Biological agents: The main biological agents available for the treatment of rheumatic diseases are tumor necrosis factor (TNF)-α antagonists, anti-CD20 monoclonal antibodies, interleukin (IL-l, IL-6) antagonists and T-cell co-stimulatory signal inhibitors. The tumor necrosis factor (TNF)-α antagonists commonly used in clinical practice include etanercept, infliXimab, adalimumab, IL-l antagonists such as anabolic acid, and anti-CD20 monoclonal antibody such as rituximab. (5) Botanicals: botanicals commonly used in the treatment of rheumatoid arthritis include rheumatism, albuglossine, and cyanophylline. The main adverse effects of these drugs are rash, hair loss, gastrointestinal reactions, bone marrow suppression, elevated liver enzymes and elevated blood creatinine. (6) Surgical treatment: For example, patients with rheumatoid arthritis can undergo synovectomy in the early stage and arthroplasty, or tendon repair or transfer in the late stage. Improve the quality of life of patients. (7) Others: including technetium-methylene diphosphonate (Yunque), which can inhibit prostaglandin synthesis, inhibit collagenase activity, prevent cartilage decomposition and destruction, and inhibit osteoclasts, and is used to treat rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and osteoporosis. There are also immunosorbent and plasma clearance therapies, which can remove circulating immune complexes from the serum and are used for ANCA-related vasculitis, lupus nephritis, etc.; intravenous gammaglobulin can be used for patients with severe systemic lupus erythematosus, dermatomyositis, and vasculitis.